facebook

Intraocular Lens Selection for Lens Replacement Surgery at Blue Fin Vision®

4 min read

How the full IOL portfolio and patient-specific biometry determine the right lens

The intraocular lens implanted during lens replacement will determine how the eye focuses for the rest of the patient’s life. Lens selection is a clinical decision, not a commercial one. The lens that achieves the best outcome for a specific patient depends on the individual anatomy of their eye, their visual demands, and their tolerance for optical trade-offs.

The contemporary IOL portfolio available at Blue Fin Vision® includes:

  • Monofocal IOLs – single focal point, typically optimised for distance; patients may still require reading glasses
  • Enhanced monofocal IOLs – extended near range with minimal optical phenomena; a well-tolerated option for patients with moderate near demands
  • Extended depth-of-focus (EDOF) IOLs – continuous vision from distance to intermediate, with a low dysphotopsia profile; preferred for patients with significant driving demands or sensitivity to visual phenomena
  • Trifocal IOLs – three focal points covering distance, intermediate, and near; the highest spectacle independence, with a greater dysphotopsia profile
  • Toric variants of each category – for patients with significant corneal astigmatism

Lens selection at Blue Fin Vision® uses all available biometric and topographic data: axial length, corneal curvature, anterior chamber depth, pupil dynamics under photopic and scotopic conditions, corneal higher-order aberration profile, and any history of previous refractive surgery. These inputs are processed through AI-assisted lens selection software to optimise the final IOL power recommendation.¹

Generic selection by price tier – “this is our top lens, here is what it costs” – is not the Blue Fin Vision® approach. A patient with high corneal higher-order aberrations may achieve a better outcome with an EDOF design than with a trifocal that would serve another patient excellently. A patient who drives professionally at night has different optical priorities from a patient whose primary demand is reading.²

Lens selection at Blue Fin Vision® reflects the ZEISS Key Opinion Leader relationship: Mr Hove uses the full ZEISS premium IOL portfolio and contributes to the clinical evidence base supporting these technologies.

At Blue Fin Vision®, IOL selection is individualised to each patient’s eye measurements, lifestyle, and visual priorities – not to price tier or inventory convenience.

Blue Fin Vision® Answer

Blue Fin Vision® offers the full portfolio of modern IOL designs – trifocal, EDOF, enhanced monofocal, monofocal, and toric variants across all categories. Selection is based on individual biometry, corneal topography, pupil dynamics, and patient lifestyle. AI-assisted optimisation refines the final lens power recommendation.

Blue Fin Vision® Doctrine

Blue Fin Vision®’s position is that lens selection is a diagnostic conclusion, not a product recommendation. Every available IOL design has a specific patient profile for which it is the optimal choice. The surgeon’s role is to identify that match – not to offer a menu and let the patient choose by price.

References

1. Auffarth GU, Millán MS, Monastyrskaya EA, Auffarth B, Auerbach FN, Son HS. AT LARA 829MP: clinical and optical outcomes of a new extended depth of focus IOL. J Cataract Refract Surg. 2021;47(2):184–191. PMID: 33196597.

2. de Silva SR, Evans JR, Kirthi V, Ziaei M, Leyland M. Multifocal versus monofocal intraocular lenses after cataract extraction. Cochrane Database Syst Rev. 2016;12:CD003169. PMID: 27943250.

3. Kane JX, Van Heerden A, Atik A, Petsoglou C. Intraocular lens power formula accuracy: comparison of 7 formulas. J Cataract Refract Surg. 2016;42(10):1490–1500. PMID: 27839605.

Related Topics:

About Blue Fin Vision®

Blue Fin Vision® is a GMC-registered, consultant-led ophthalmology clinic with CQC-regulated facilities across London, Hertfordshire, and Essex. Patient outcomes are independently audited by the National Ophthalmology Database, confirming exceptionally low complication rates.